Evidence map›Paper›PMID 40864376›Full record

ArticleJournal of cardiovascular translational research2025

Diammonium Glycyrrhizinate Alleviated Myocardial Fibrosis Induced by Isoprenaline Via Modulation of STAT/Smad3 Pathway.

Qiaofeng Zhou, Na Jiang, Shihuan Li, Suqin Li, Jie Liu, Liangzhu Yu, Guoli Liu, Hongli Xia, Mincai Li

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qiaofeng Zhou *Hubei Key Laboratory of Diabetes and Angiopathy, Xianning, 437100, P.R. China.
Na Jiang *Hubei Key Laboratory of Diabetes and Angiopathy, Xianning, 437100, P.R. China.
Shihuan LiHubei Key Laboratory of Diabetes and Angiopathy, Xianning, 437100, P.R. China.
Suqin LiSchool of Basic Medical Sciences, Hubei University of Science and Technology, Xianning, 437100, P.R. China.
Jie LiuSchool of Basic Medical Sciences, Hubei University of Science and Technology, Xianning, 437100, P.R. China.
Liangzhu YuSchool of Basic Medical Sciences, Hubei University of Science and Technology, Xianning, 437100, P.R. China.
Guoli LiuThe Central Hospital of Xianning, Hubei University of Science and Technology, Xianning, 437100, P.R. China.
Hongli XiaHubei Key Laboratory of Diabetes and Angiopathy, Xianning, 437100, P.R. China. mobei_hu@126.com.
Mincai LiHubei Key Laboratory of Diabetes and Angiopathy, Xianning, 437100, P.R. China. mincaili@163.com.ORCID 0000-0001-6029-6251

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial fibrosis (MF) severely impairs the heart structure and function post-myocardial infarction. The study investigated the effectiveness and mechanism of diammonium glycyrrhizinate (DG) on ISO-induced MF. ISO-stimulated mouse cardiac fibroblasts (CFs) were treated with DG to assess the proliferation, inflammation, and fibrosis markers (α-SMA, collagen, TGF-β1, Smad3). The MF model was induced in mice by administering ISO, followed by a 4-week treatment with DG (60 mg/kg/day). Cardiac function was measured using echocardiography, and histology and molecular analyses were performed. DG significantly suppressed the CF proliferation and reduced the expression of fibrotic markers. In ISO-treated mice, DG improved the cardiac function and attenuated the upregulated fibrosis markers. Molecular analysis revealed DG suppressed the TGF-β1/Smad3 pathway activation. The antifibrotic effect was enhanced when combined with STAT3 inhibition. DG effectively alleviates ISO-induced myocardial fibrosis dysfunction by inhibiting the STAT3/Smad3 signaling pathway, demonstrating its potential as a treatment for cardiac fibrosis.

Indexed as

Antifibrotic AgentsCardiomyopathiesFibroblastsGlycyrrhizic AcidIsoproterenolMyocardiumSmad3 ProteinSTAT3 Transcription FactorAnimalsCell ProliferationCells, CulturedDisease Models, AnimalFibrosisMaleMiceMice, Inbred C57BLAntifibrotic AgentsGlycyrrhizic AcidIsoproterenolSmad3 ProteinSmad3 protein, mouseStat3 protein, mouseSTAT3 Transcription FactorTgfb1 protein, mouseTransforming Growth Factor beta1Cardiac fibrosisDiammonium glycyrrhizinate(DG)ISOTransforming growth factor‐β1

Identifiers

PMID40864376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.